Table 2 Lymphocyte subpopulations in newborns and non-smoking (NSM) and smoking mothers (SM)
From: Maternal cigarette smoking and its effect on neonatal lymphocyte subpopulations and replication
Newborns | Mothers | |||
|---|---|---|---|---|
NSM (n = 111) | SM (n = 58) | NSM (n = 111) | SM (n = 58) | |
Leucocytes/μl | 11948 ± 3771 (11340; 5440 – 23980) | 11285 ± 2796 (11600; 4570 – 16810) | 11863 ± 5040 (11180; 4140 – 25510) | 13404 ± 4390 (12700; 6980 – 21520) |
Lymphocytes/μl | 4084 ± 1263 (3800; 1580 – 8500) *** | 4046 ± 1057 (3930; 2320 – 6100)*** | 1277 ± 493 (1250; 480 – 2660) | 1897 ± 722 (1810; 900 – 4260) ***1) |
CD3+ (% of lymphocytes) | 69.2 ± 8.8 (69.4; 51.6 – 86.7) | 68.8 ± 8.7 (68.3; 50.5 – 90.3) | 80.1 ± 6.9 (80.8; 56.6 – 91.6) | 79.8 ± 6.9 (80.3; 62.1 – 91.6) |
CD19+ (% of lymphocytes) | 16.9 ± 6.2 (15.2; 5.0 – 35.1) | 18.2 ± 4.9 (18.4; 8.6 – 26.3) | 10.2 ± 4.3 (9.3; 2.8 – 24.4) | 12.1 ± 5.5 (11.5; 4.6 – 27.5) |
CD16+/56+ (% of lymphocytes) | 13.8 ± 8.5 (11.4; 3.0 – 39.5) | 13.1 ± 7.6 (12.5; 1.1 – 26.5) | 9.7 ± 7.0 (7.8; 1.9 – 38.6) | 8.1 ± 4.7 (7.6; 1.7 – 25.1) |
CD4/CD8 | 2.5 ± 0.9 (2.4; 0.9 – 5.0) | 2.4 ± 0.7 (2.4; 1.3 – 3.8) | 1.7 ± 0.6 (1.6; 0.7 – 3.2) | 1.8 ± 0.6 (1.7; 0.9 – 3.9) |
CD4+ (% of CD3+) | 69.7 ± 8.1 (70.8; 48.8 – 83.4) | 69.5 ± 6.0 (70.1; 56.3 – 79.3) | 61.2 ± 8.0 (61.5; 41.9 – 75.9) | 61.9 ± 7.9 (63.3; 46.4 – 79.8) |
CD8+ (% of CD3+) | 30.4 ± 8.1 (29.2; 16.6 – 51.2) | 30.5 ± 6.1 (29.8; 20.7 – 43.8) | 38.8 ± 8.0 (38.5; 23.9 – 58.0) | 38.0 ± 7.9 (36.7; 20.3 – 53.6) |
CD45RA + CD28 + CD62L + (% of CD4+) | 85.3 ± 8.9 (85.4; 48.4 – 94.8) | 86.7 ± 6.6 (87.5; 70.8 – 98.6) | 45.1 ± 14.1 (45.6; 19.5 – 62.4) ***2) | 42.4 ± 12.1 (44.1; 20.6 – 67.2) ***2) |
CD45RA + CD28 + CD62L + (% of CD8+) | 59.3 ± 12.9 (58.9; 20.5 – 85.7) | 60.5 ± 10.9 (59.1; 31.6 – 77.3) | 38.8 ± 17.6 (36.9; 12.0 – 83.3) ***2) | 37.4 ± 11.5 (38.8; 11.2 – 59.0) ***2) |
CD45RO + CD27 + CD28+ (% of CD4+) | 4.9 ± 2.4 (4.7; 0.5 – 11.9) ***3) | 4.7 ± 1.9 (4.8; 0.6 – 9.2) ***3) | 34.3 ± 10.6 (33.1; 14.2 – 65.2) | 37.1 ± 8.5 (38.5; 17.6 – 51.0) |
CD45RO + CD27 + CD28+ (% of CD8+) | 3.4 ± 1.7 (3.4; 0.0 – 9.3) ***3) | 3.1 ± 1.8 (3.1; 0.0 – 7.2) ***3) | 13.4 ± 7.6 (11.8; 3.2 – 49.1) | 12.1 ± 5.8 (10.4; 3.7 – 24.5) |
CD45RO + CD27-CD28-(% of CD4+) | 0.3 ± 0.5 (0.1; 0.0 – 2.5) ***3) | 0.4 ± 0.5 (0.1; 0.0 – 2.0) ***3) | 2.1 ± 3.1 (0.7; 0.1 – 18.1) | 1.5 ± 2.4 (0.6; 0.1 – 11.1) |
CD45RO + CD27-CD28-(% of CD8+) | 0.3 ± 0.7 (0.1; 0.0 – 4.3) ***3) | 0.2 ± 0.4 (0.0; 0.0 – 2.0) ***3) | 4.0 ± 6.4 (2.5; 0.1 – 22.0) | 2.8 ± 3.5 (1.8; 0.1 – 18.6) |
CD45RA + CD28- (% of CD4+) | 0.05± 0.2 (0.0; 0.0 – 1.7) ***3) | 0.02 ±0.04 (0.0; 0.0 – 0.1) ***3) | 1.0 ± 1.8 (0.2; 0.1 – 7.8) | 0.9 ± 2.4 (0.2; 0.1 – 11.9) |
CD45RA + CD28- (% of CD8+) | 3.3 ± 4.9 (2.4; 0.3 – 4.8) ***3) | 2.2 ± 1.1 (2.3; 0.1 – 6.1) ***3) | 16.9 ± 12.9 (14.6; 0.4 – 57.9) | 16.7 ± 11.9 (13.8; 1.0 – 40.9) |
CD4 + CD25++ (% of CD3+) | 6.1 ± 2.9 (6.6; 0.0 – 11.7) | 6.0 ± 3.3 (7.3; 0.0 – 10.7) | 5.4 ± 3.9 (5.2; 0.1 – 17.0)*4) | 6.2 ± 4.7 (6.1; 0.1 – 17.7) |